Tag Archives: Achillion Pharmaceuticals

Vertex Pharma (NASDAQ:VRTX) Shares Climbed 50% on Green Mountain- VRTX, IDIX, HGSI, VVUS, DNDN, ACHN, GILD

Posted on May 8, 2012 by Thomas Vedder

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) jumped almost 50% in pre-market trading Monday following the drug developer posted it saw larger than anticipated results in a mid-stage study of a potential treatment for the nearly all severe form of cystic …

Posted in Healthcare, Latest Headlines | Tagged Achillion Pharmaceuticals, ACHN, Dendreon, DNDN, GILD, Gilead Sciences, HGSI, Human Genome Sciences, Idenix Pharmaceuticals, IDIX, NASDAQ:ACHN, NASDAQ:DNDN, NASDAQ:GILD, NASDAQ:HGSI, NASDAQ:IDIX, NASDAQ:VRTX, NASDAQ:VVUS, Vertex Pharmaceuticals, Vivus, VRTX, VVUS | Comments Off

Healthcare Sector; Two Vice Versa Stocks- NASDAQ:ACHN, NASDAQ:AMLN, NYSE:GS

Posted on April 24, 2012 by Thomas Vedder

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) shares dropped as a Phase II study data for its escort hepatitis C treatment was believed unsatisfactory in light of the current success of peers. While lots of investment banks are optimistic about Achillion, JMP Group …

Posted in Healthcare, Latest Headlines | Tagged Achillion Pharmaceuticals, ACHN, AMLN, Amylin Pharmaceuticals, NASDAQ:ACHN, NASDAQ:AMLN | Comments Off

Human Genome Say No to Glaxo’s $2.6 Billion Cash Offer – HGSI, GSK, BIIB, EBS, GILD, BSX, ARNA, ACHN, ABT, JNJ

Posted on April 19, 2012 by Geoff Noir

Human Genome Sciences (NASDAQ:HGSI) above doubled in trading as the biotechnology firm put itself up for sale later than refusing a $2.59 billion acquisition proposal from GlaxoSmithKline plc (ADR) (NYSE:GSK).

Human Genome announced in a statement Glaxo’s $13-per-share cash offer, …

Posted in Healthcare, Latest Headlines | Tagged Abbott, Achillion Pharmaceuticals, Arena Pharmaceuticals, Biogen Idec, Boston Scientific, Emergent Biosolutions, Gilead Sciences, GlaxoSmithKline, GSK, HGSI, Human Genome Sciences, Johnson & Johnson, NASDAQ:ACHN, NASDAQ:ARNA, NASDAQ:BIIB, NASDAQ:GILD, NASDAQ:HGSI, NYSE:ABT, NYSE:BSX, NYSE:EBS, NYSE:GSK, NYSE:JNJ | Comments Off

What the fuss Achillion Pharmaceuticals and FreightCar America?

Posted on February 17, 2012 by Martin Timble

In this report: Achillion Pharmaceuticals (NASDAQ:ACHN) and FreightCar America (NASDAQ:RAIL).

Achillion Pharmaceuticals (NASDAQ:ACHN) shares surged 26 percent on Friday after the company’s competitor Gilead Sciences announced the results of its hepatitis C treatment which it received after acquiring Pharmasset for …

Posted in Latest Headlines, Reports | Tagged Achillion Pharmaceuticals, ACHN, FreightCar America, NASDAQ:ACHN, NASDAQ:RAIL, RAIL | Comments Off

3 stocks to watch on Wednesday: CSTR, LEG, ACHN

Posted on February 7, 2012 by Geoff Noir

In this report: Coinstar Inc. (NASDAQ:CSTR), Leggett & Platt Inc. (NYSE:LEG) and Achillion Pharmaceuticals (NASDAQ:ACHN).

Coinstar Inc. (NASDAQ:CSTR) shares will be worth watching on Wednesday after the company’s shares gained nearly 14 percent on news that the company would joint …

Posted in Latest Headlines, Reports | Tagged Achillion Pharmaceuticals, ACHN, Coinstar Inc., CSTR, LEG, Leggett & Platt Inc., NASDAQ:ACHN, NASDAQ:CSTR, NYSE:LEG | Comments Off

Friday’s sinking stocks and the reasons why (THS, CCOI, ACHN)

Posted on January 20, 2012 by Josie Middleton

In this report: Treehouse Foods (NYSE:THS), Cognet Communications Group (NASDAQ:CCOI) and Achillion Pharmaceuticals (NASDAQ:ACHN).

Treehouse Foods (NYSE:THS) is trading over 11 percent lower today after the company released a weaker than expected forecast for the fourth quarter as unseasonably warm …

Posted in Latest Headlines, Reports | Tagged Achillion Pharmaceuticals, ACHN, Analysts, CCOI, charged, Cognet Communications Group, company, copyright, earnings, expecting, FBI, Federal Bureau of Investigation, forecast, hepatitis C, infringement, Megaupload.com, NASDAQ, NASDAQ:ACHN, NASDAQ:CCOI, NYSE, NYSE:THS, outlook, quarter, seeking alpha, shares, THS, trading, Treehouse Foods, Wall Street | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.